David Turkaly, an analyst from JMP Securities, reiterated the Buy rating on Integra Lifesciences (IART – Research Report). The associated price target is $35.00.
David Turkaly has given his Buy rating due to a combination of factors that suggest potential growth for Integra LifeSciences. The company, under the leadership of its new CEO Mojdeh Poul, is navigating through a transitional phase with a new compliance master plan. Poul’s extensive experience in the MedTech industry is seen as a positive influence in steering the company through these challenges.
Despite some choppy results in the fourth quarter of 2024, Integra LifeSciences showed resilience with mostly in-line revenue and EBITDA, and some upside in EPS. The company’s diversified portfolio, particularly in the Codman Specialty Surgical segment, and strategic transactions like the Acclarent deal, are expected to drive growth once current operational headwinds subside. These factors, along with a stable price target based on future earnings estimates, underpin Turkaly’s optimistic outlook on the stock.